IDYA News and Press, IDEAYA Biosciences Inc. From 12/14/23

2023-12-14 00:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-05 15:01:27 ET Summary Ideaya Biosciences uses synthetic lethality to target cancer cells and has seen its stock double since March. Synthetic lethality can selectively target cancer cells while sparing normal cells, offering a promising therapeutic strategy. Ideaya's ...

IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discov...

2023-12-04 09:50:28 ET More on SPDR S&P 500 ETF Trust: Bears Refuse To Acknowledge New All-Time Highs In 2024 SPY Is A Buy According To The 200-Day Simple Moving Average When Do You Take Profits? Top 10 trades for 2024 - BofA S&P 500 hits new ...

IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer PR Newswire Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibi...

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 PR Newswire SOUTH SAN FRANCISCO, Calif. , Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NAS...

2023-11-17 18:40:33 ET Summary Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by ...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

IDEAYA Biosciences Inc. (IDYA) is expected to report $-0.47 for Q3 2023

2023-11-07 06:28:59 ET More on IDEAYA Biosciences IDEAYA's Triple Threat: Melanoma, Money, And Momentum Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead IDEAYA Biosciences down 9%, prices $125M offering IDEAYA announces proposed public ...